% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@INPROCEEDINGS{Kasper:1005587,
author = {Kasper, Jan and Caspers, Svenja and Lotter, Leon and
Hoffstaedter, Felix and Eickhoff, Simon and Dukart, Jürgen},
title = {{B}rain function neurotransmitter co localization:
{E}ffects of aging and deviations in {P}arkinson’s
disease},
reportid = {FZJ-2023-01546},
year = {2023},
abstract = {Neurodegenerative diseases exhibit a specific spatial
pattern of altered brain activity as capturedby
resting-state fMRI[1]. In Parkinson’s disease (PD), areas
with the most severe alterations inbrain activity
co-localize with higher density of specific neurotransmitter
systems[2], indicatingincreased vulnerability of respective
neural cell populations. Such vulnerability may also be
reflectedin a deviation from normal associations between
brain activity and specific neurotransmittersystems. Here,
we test this hypothesis by computing normative models of
co-localization ofneurotransmitter systems and brain
activity in a large cohort of healthy subjects. We then
examinedeviations from these models in PD.We computed
individual maps of voxel-wise (3 $mm^3)$ brain activity at
rest (fractional amplitudeof low-frequency fluctuations,
fALFF; local correlation, LCOR) and connectivity measures
(globalcorrelation, GCOR) of 25,917 healthy subjects (age:
mean ± SD, range: 64 ± 7.5, [44 – 82]; $46\%$ male)from
the UK-Biobank. Individual levels of co-localization
(Fisher’s z(Spearman ρ)) of all threemeasures and 19
neurotransmitter systems (dopamine, serotonin,
norepinephrine, acetylcholine,glutamate, cannabinoid,
opioid, and GABA) were obtained by spatial correlation
analyses. Effectsof aging and sex differences in these
levels were identified via linear regression and
two-samplet-tests. We modeled the level of co-localization
with age and sex as covariates using Bayesianlinear
regression implemented in the PCNtoolkit[3]. Deviations
(z-scores) from these models werecalculated for patients
with PD (n=58, age[yr]: 68 ± 6.5, [52-80]; $male:55\%,$
from UKBiobank) andexamined for correlations with disease
duration. For interpretation of aging effects,
voxel-wiselinear effects of aging in all three measures were
also examined for associations with specificneurotransmitter
systems. All analyses were corrected for multiple
comparisons (pcorr<0.05).The spatial distribution of
serotonergic, dopaminergic, glutamatergic, opioid, and
GABAergic systemsexplained more than 5 $\%$ in fALFF, LCOR,
and GCOR variance. Co-localization levels of allthree
measures changed significantly with age (maximum explained
variance: $4.6\%)$ and showedsex differences (maximum
Cohen’s d: 0.38) in most of the systems. Patients with PD
exhibitedsignificantly lower co-localizations (z-range:-0.26
to -0.64) regarding all measures with 5-HT1b,5-HT6, D1, D2,
GABAa, H3, M1, mGluR5, NMDA, and transporters of dopamine,
serotonin, norepinephrineand acetylcholine. Deviation from
LCOR-GABAa association was correlated with diseaseduration
(pFDR=0.027, r=-0.38). Figure 1 shows representative models.
Wide-spread agerelatedalteration in all three measures were
found in the healthy population. For fALFF, thevoxel-wise
age-effects were associated with the availability of
norepinephrine transporters, 5-HT4,5-HT6, D2, GABAa, and
NMDA. For LCOR, associations were found with NMDA and
transportersof norepinephrine, dopamine, serotonin, and
acetylcholine availability, and for GCOR with thetransporter
of norepinephrine.Here, we find that the co-localization of
resting-state activity estimates with neurotransmitter
systemsfollows sex-specific patterns during healthy aging
and that patients with PD deviate from thisnormative
development in dopaminergic, serotonergic, norepinephrine,
GABAergic, histaminergic,acetylcholinergic, and
glutamatergic systems. Given that all of the indicated
transmitter systemsare affected in PD[4–16], these
findings suggest that rs-fMRI-neurotransmitter
co-localizationmay indeed reflect individual and
neurotransmitter specific neuropathology, necessitating
furtherresearch into the value of cross-modal brain-wide
co-localization estimates as PD biomarkers.},
month = {Apr},
date = {2023-04-04},
organization = {General Assembly of the Joint Lab
Supercomputing and Modeling for the
Human Brain, Jülich (Germany), 4 Apr
2023 - 5 Apr 2023},
subtyp = {After Call},
cin = {INM-7 / INM-1},
cid = {I:(DE-Juel1)INM-7-20090406 / I:(DE-Juel1)INM-1-20090406},
pnm = {5251 - Multilevel Brain Organization and Variability
(POF4-525)},
pid = {G:(DE-HGF)POF4-5251},
typ = {PUB:(DE-HGF)6},
doi = {10.34734/FZJ-2023-01546},
url = {https://juser.fz-juelich.de/record/1005587},
}